The CD4/CD8 ratio of tumor-infiltrating lymphocytes at the tumor-host interface has prognostic value in triple-negative breast cancer.

Compelling evidence has demonstrated the prognostic value of tumor-infiltrating lymphocytes (TILs), especially in triple-negative breast cancer (TNBC). However, only a limited number of studies to investigate the importance of the subsets of T cells in TILs have been carried out, less so the significance of the location of these TILs. In this study, we explored in a cohort of 42 consecutive TNBC cases the prognostic significance of TIL subsets at the tumor-host interface (within 1 high-power field [0.5 mm] of the invasive front) and compared them with TILs within the intratumoral stroma. Given the reported importance of TILs in HER2-overexpressing breast cancer, a subset of such tumors was also included for comparison. The range was wide in both locations; nevertheless, the mean CD4+ and CD8+ T cell count was significantly higher at the tumor-host interface than that found within the intratumoral stroma (both P<.0001). The number of CD4+ or CD8+ T cells at either location was not significantly associated with distant relapse-free or overall survival. However, the CD4/CD8 ratio at the tumor-host interface was significantly associated with both relapse-free survival (hazard ratio 0.2, P=.002) and overall survival (hazard ratio 0.13, P=.002), whereas this association was not seen for the CD4/CD8 ratio within the intratumoral stroma. As expected, both tumor size and nodal status were significantly associated with survival outcomes. The findings further support the contention that TILs, as markers of regional immune escape, are of prognostic importance in TNBC progression and that the CD4/CD8 ratio of TILs at the tumor-host interface plays a distinctive role, thus appearing to be of clinical relevance.

[1]  Molin Wang,et al.  Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  F M Blows,et al.  Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  G. Tse,et al.  Lymphocytic infiltrate is associated with favorable biomarkers profile in HER2-overexpressing breast cancers and adverse biomarker profile in ER-positive breast cancers , 2013, Breast Cancer Research and Treatment.

[4]  A. Campbell,et al.  Flow cytometric analysis of tumour-draining lymph nodes in breast cancer patients. , 1992, European journal of cancer.

[5]  A. Rubbert,et al.  Functional characterization of tumor‐infiltrating lymphocytes, lymph‐node lymphocytes and peripheral‐blood lymphocytes from patients with breast cancer , 1991, International journal of cancer.

[6]  M. Piccart,et al.  Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial , 2017, Journal of the National Cancer Institute.

[7]  E. Gonzalez-Billalabeitia,et al.  Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer , 2014, Breast Cancer Research.

[8]  Stefan Michiels,et al.  Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  M. Yamaguchi,et al.  Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer. , 2012, Human pathology.

[10]  P. Tan,et al.  Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer , 2016, Breast Cancer Research and Treatment.

[11]  T. Nielsen,et al.  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  A single-centre chart review exploring the adjusted association between breast cancer phenotype and prognosis. , 2011, Current oncology.

[13]  A. Ribeiro-Silva,et al.  Tumor-infiltrating CD4+ T lymphocytes in early breast cancer reflect lymph node involvement. , 2006, Clinics.

[14]  W. Foulkes,et al.  Prognostic significance of CD8+ T lymphocytes in breast cancer depends upon both oestrogen receptor status and histological grade , 2011, Histopathology.

[15]  Tumor-infiltrating lymphocytes in breast cancer: ready for prime time? , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  E. Zhou,et al.  Intratumoral CD8+ Cytotoxic Lymphocyte Is a Favorable Prognostic Marker in Node-Negative Breast Cancer , 2014, PloS one.

[17]  S. Leung,et al.  CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer , 2012, Breast Cancer Research.

[18]  C. Gerlinger,et al.  Identification of prognostic different subgroups in triple negative breast cancer by Her2-neu protein expression , 2014, Archives of Gynecology and Obstetrics.

[19]  Harry Bartelink,et al.  Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas , 2007, Breast Cancer Research.

[20]  G. D. de Bock,et al.  The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis , 2011, British Journal of Cancer.

[21]  Carsten Denkert,et al.  Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  R. Gelber,et al.  Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00 , 2016, Breast Cancer Research and Treatment.

[23]  Ian O Ellis,et al.  Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  K. Knutson,et al.  Tumor antigen-specific T helper cells in cancer immunity and immunotherapy , 2005, Cancer Immunology, Immunotherapy.

[25]  Carsten Denkert,et al.  Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial. , 2015, JAMA oncology.

[26]  S. Rosenberg,et al.  CD4+ T lymphocytes infiltrating human breast cancer recognise autologous tumor in an MHC-class-II restricted fashion , 2005, Cancer Immunology, Immunotherapy.

[27]  S. Pyrhönen,et al.  The prognostic role of CD4+ and CD8+ lymphocytes during chemoimmunotherapy in metastatic melanoma , 2004, Melanoma research.

[28]  A. Fattorossi,et al.  Lymphocyte populations in human lymph nodes. Alterations in CD4+ CD25+ T regulatory cell phenotype and T‐cell receptor Vβ repertoire , 2003, Immunology.

[29]  Z. Ren,et al.  Breast cancer subtypes predispose the site of distant metastases. , 2015, American journal of clinical pathology.

[30]  Yul Ri Chung,et al.  Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status , 2017, Breast Cancer Research and Treatment.

[31]  Hongwei Chen,et al.  A reversed CD4/CD8 ratio of tumor-infiltrating lymphocytes and a high percentage of CD4+FOXP3+ regulatory T cells are significantly associated with clinical outcome in squamous cell carcinoma of the cervix , 2010, Cellular and Molecular Immunology.

[32]  S Michiels,et al.  Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  R. Matkowski,et al.  The prognostic role of tumor-infiltrating CD4 and CD8 T lymphocytes in breast cancer. , 2009, Anticancer research.

[34]  Kathleen A Cronin,et al.  US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. , 2014, Journal of the National Cancer Institute.

[35]  C. Sotiriou,et al.  Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer , 2017, Journal of the National Cancer Institute.

[36]  R. Sakalauskas,et al.  The prognostic influence of tumor infiltrating Foxp3+CD4+, CD4+ and CD8+ T cells in resected non-small cell lung cancer , 2015, Journal of Inflammation.

[37]  B. Sheu,et al.  Reversed CD4/CD8 ratios of tumor‐infiltrating lymphocytes are correlated with the progression of human cervical carcinoma , 1999, Cancer.

[38]  C. Croce,et al.  Pluripotent stem cell miRNAs and metastasis in invasive breast cancer. , 2014, Journal of the National Cancer Institute.

[39]  S. Vowler,et al.  Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation. , 2006, Journal of hepatology.

[40]  R. Schreiber,et al.  Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.

[41]  D. Yin,et al.  CD8+ cytotoxic T cell and FOXP3+ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes , 2011, Breast Cancer Research and Treatment.

[42]  Jae Hyun Kim,et al.  Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer , 2013, British Journal of Cancer.